TRADITIONAL RISK FACTORS FOR CARDIOVASCULAR DISEASES IN SYSTEMIC SCLEROSIS AND THEIR RELATIONSHIP TO STRUCTURAL CHANGES OF THE HEART

Objective: to determine the frequency of traditional risk factors (TRFs) for cardiovascular diseases (CVD) in patients with systemic sclerosis (SS) and to analyze their relationship to the clinical manifestations of SS, as well as to structural changes, as evidenced by echocardiography (EchoCG).

Subjects and methods. The investigation enrolled 125 patients with SS and 50 sex- and age-matched, apparently healthy individuals included in a control group. Standard electrocardiography was performed in all and EchoCG – in 121 patients. The Systematic Coronary Risk Evaluation (SCORE) scale was used to assess the risk of fatal CVD in 100 patients with SS and in 47 control individuals within 10 years.

Results and discussion. The frequency of TFRs in patients with SS was not significantly different from that in the control group, except for the occurrence of hypercholesterolemia and increased body mass index (BMI). In SS, BMI >25 kg/m2 was observed significantly more often and the frequency of hypercholesterolemia was lower than in the controls (p <0.018). Hypertension and diabetes mellitus were slightly more frequently encountered in SS patients than in the controls, but this difference was insignificant. Taking into account the Russian Society of Cardiology (RSC) guidelines, the cardiovascular risk (CVR) was assessed with the SCORE scale. A very high CVR was much more common in SS and a moderate CVR was much more frequently seen in the control group. There were no substantial differences in the frequency of low and high CVRs. SS is characterized by the increased frequency of high total CVD risk as compared to the controls. Hypertension, overweight, and over 50 years of age were associated with more obvious structural heart disease.

Conclusion. TRFs make a substantial contribution to the formation of a high CVR in patients with SS, promoting the development of atherosclerosis and its complications. Assessment of TGFs in SS patients will facilitate identifying patients at high risk for cardiovascular death and timely prescribing therapy. Hypertension is an important TGF that in SS is associated with considerable structural changes in the heart; therefore adequate blood pressure control is of importance in improving SS prognosis especially in patients older than 50 years.

1. Rabquer BJ, Koch AE. Angiogenesis and vasculopathy in systemic sclerosis: evolving concepts. Curr Rheumatol Rep. 2012 Feb;14(1):56-63. doi: 10.1007/s11926-011-0219-1

2. Radiс M, Kaliterna DM, Fabijanic D, Radic J. [Systemic sclerosis – pathogenesis, clinical manifestations and treatment]. Lijec Vjesn. 2010 May-Jun;132(5-6):162-8 (In Croat.).

3. Sherer Y, Shoenfeld Y. Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol. 2006 Feb;2(2):99-106. doi: 10.1038/ncprheum0092

4. Nassenstein K, Breuckmann F, Huger M, et al. Detection of myocardial fibrosis in systemic sclerosis by contrast-enhanced magnetic resonance imaging. Rofo. 2008 Dec;180(12):1054- 60. doi: 10.1055/s-2008-1027864

5. Ngian GS, Sahhar J, Proudman SM, et al. Prevalence of coronary heart disease and cardiovascular risk factors in a national crosssectional cohort study of systemic sclerosis. Ann Rheum Dis. 2012;71:1980-3. doi: 10.1136/annrheumdis-2011-201176

6. Bryan C, Howard Y, Brennan P, et al. Survival following the onset of scleroderma: results from a retrospective inception cohort study of the patients population. Br J Rheumatol. 1996;35:1122-6. doi: 10.1093/rheumatology/35.11.1122

7. Szekanecz Z, Koch AE. Vascular involvement in rheumatic diseases: vascular rheumatology. Arthritis Res Ther. 2008;10(5):224. doi: 10.1186/ar2515

8. Belch JJ, McSwiggan S, Lau C. Macrovascular disease in systemic sclerosis: the tip of an iceberg? Rheumatology. 2008;47 Suppl 5:v17. doi: 10.1093/rheumatology/ken280

9. Toms TE, Panoulas VF, Kitas GD. Dyslipidaemia in rheumatological autoimmune diseases. Open Cardiovasc Med J. 2011;5:64-75. doi: 10.2174/1874192401105010064

10. Sitia S, Atzeni F, Sarzi-Puttini P. Cardiovascular involvement in systemic autoimmune diseases. Autoimmun Rev. 2009 Feb;8(4):281-6. doi: 10.1016/j.autrev.2008.08.004

11. Szekanecz Z, Kerekes G, Der H, et al. Accelerated atherosclerosis in rheumatoid arthritis. Ann NY Acad Sci. 2007;1108:349-58. doi: 10.1196/annals.1422.036

12. Shoenfeld Y, Gerli R, Doria A, et al. Accelerated atherosclerosis in aytoimmune diseases. Circulation. 2005;112:3337-47. doi: 10.1161/CIRCULATIONAHA.104.507996

13. Szucs G, Timar O, Szekanecz Z. Endothelial dysfunction precedes atherosclerosis in systemic sclerosis – relevance for prevention of vascular complications. Rheumatology (Oxford). 2007 May;46(5):759-62. doi: 10.1093/rheumatology/kel426

14. Szekanecz Z, Shoenfeld Y. Lupus and cardiovascular disease: the facts. Lupus. 2006;15 Suppl:3-10. doi: 10.1177/0961203306071665

15. Soltesz P, Szekanecz Z, Kiss E, Shoenfeld Y. Cardiac manifestations in antiphospholipid syndrome. Autoimmun Rev. 2007;6:379-86. doi: 10.1016/j.autrev.2007.01.003

16. Hollan I, Meroni P, Ahearn J, et al. Cardiovascular disease in autoimmune rheumatic diseases. Autoimmun Rev. 2013 Aug;12(10):1004-15. doi: 10.1016/j.autrev.2013.03.013

17. Hettema ME, Bootsma H, Kallenbrg CGM. Macrovascular disease and atherosclerosis in systemic sclerosis. Rheumatology. 2008;47:578-83. doi: 10.1093/rheumatology/ken078

18. Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010 Oct;69(10):1809-15. doi: 10.1136/ard.2009.114264

19. Ioannidis JPA. Large scale evidence and replication: insights from rheumatology and beyond. Ann Rheum Dis. 2005;64:345-6. doi: 10.1136/ard.2004.027979

20. Dave AJ, Fiorentino D, Lingala B, et al. Atherosclerotic cardiovascular disease in hospitalized patients with systemic sclerosis: higher mortality than patients with lupus and rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014 Feb;66(2):323-7. doi: 10.1002/acr.22152

21. Sander GE, Giles TD. Cardiovascular complications of collagen vascular disease. Curr Treat Opt Cardiovasc Med. 2002 Apr;4(2):151-9. doi: 10.1007/s11936-002-0035-z

22. Masi AT, Rodnan GP, Medsger TA, et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980;23(5):581-90. doi: 10.1002/art.1780230510

23. Jordan S, Maurer B, Michel B, Distler O. Performance of the new EULAR/ACR classification criteria for systemic sclerosis in clinical practice. Ann Rheum Dis. 2013;72 Suppl 3:60. doi: 10.1136/annrheumdis-2013-eular.239

24. Man A, Zhu Y, Zhang Y, et al. The risk of cardiovascular disease in systemic sclerosis: a population-based cohort study. Ann Rheum Dis. 2013;72:188-93. doi: 10.1136/annrheumdis-2012-202007

25. Khurma V, Meyer C, Park GS, et al. A pilot study of subclinical coronary atherosclerosis in systemic sclerosis: coronary artery calcification in cases and controls. Arthritis Rheum. 2008;59:591-7. doi: 10.1002/art.23540

26. Mok MY, Lau CS, Chiu SS, et al. Systemic sclerosis is an independent risk factor for increased coronary artery calcium deposition. Arthritis Rheum. 2011;63:1387-95. doi: 10.1002/art.30283

27. Nordin A, Jensen-Urstad K, Bjornadal L, et al. Ischemic arterial events and atherosclerosis in patients with systemic sclerosis: a population-based case-control study. Arthritis Res Ther. 2013;15:R87. doi: 10.1186/ar4267

28. Хрипунова АА. Частота макрососудистых осложнений при системной склеродермии и прогностическое значение в их развитии традиционных кардиоваскулярных факторов риска и иммуновоспалительных механизмов: Дисс. … канд. мед. наук. Ставрополь; 2012 [Khripunova AA. Chastota makrososudistykh oslozhnenii pri sistemnoi sklerodermii i prognosticheskoe znachenie v ikh razvitii traditsionnykh kardiovaskulyarnykh faktorov riska i immunovospalitel'nykh mekhanizmov: Diss. … kand. med. nauk [The frequency of macrovascular complications of systemic sclerosis and their prognostic significance in the development of traditional cardiovascular risk factors and immunoinflammatory mechanisms: Diss. ... Cand. Med. Sci.]. Stavropol'; 2012].

29. Патрикеева ДА. Клинико-диагностическое значение дисфункции почек как фактора риска кардиоваскулярной патологии у больных системной склеродермией: Дисс. … канд. мед. наук. Волгоград; 2015 [Patrikeeva DA. Kliniko-diagnosticheskoe znachenie disfunktsii pochek kak faktora riska kardiovaskulyarnoi patologii u bol'nykh sistemnoi sklerodermiei: Diss. … kand. med. nauk [Clinical and diagnostic value of renal dysfunction as a risk factor for cardiovascular disease in patients with systemic sclerosis: Diss. ... Cand. Med. Sci.]. Volgograd; 2015].

30. Lippi G, Caramaschi P, Montagnana M, et al. Lipoprotein and the lipid profile in patients with systemic sclerosis. Clinica Climica Acta. 2006;364(1-2):345-8. doi: 10.1016/j.cca.2005.07.015

31. Cerinic MM, Valentini G, Sorano GG, et al. Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis. Semin Arthritis Rheum. 2003;32(5):285-95. doi: 10.1053/sarh.2002.50011

32. Borba EF, Borges CTL, Bonfa E. Lipoprotein profile in limited systemic sclerosis. Rheumatol Int. 2005;25:379-83. doi: 10.1007/s00296-004-0580-8

33. Tsifetaki N, Georgiadis AN, Alamanos Y, et al. Subclinical atherosclerosis in scleroderma patients. Scand J Rheumatol. 2010;39(4):326-9. doi: 10.3109/03009741003605648

34. Schiopu E, Karen M, McMahon Maureen A, et al. Prevalence of subclinical atherosclerosis is increased in systemic sclerosis and is associated with serum proteins: a cross-sectional, controlled study of carotid ultrasound. Rheumatology. 2014;53:704-13. doi: 10.1093/rheumatology/ket411

35. Frerix M, Stegbauer J, Kreuter A, Weiner SM. Atherosclerotic plaques occur in absence of intima-media thickening in both systemic sclerosis and systemic lupus erythematosus: a duplex sonography study of carotid and femoral arteries and follow-up for cardiovascular events. Arthritis Res Ther. 2014 Feb 19;16(1):R54. doi: 10.1186/ar4489

36. Chu S-Y, Chen Y-J, Liu C-J, et al. Increased risk of acute myocardial infarction in systemic sclerosis: a nationwide population-based study. Amer J Med. 2013;126:982-8. doi: 10.1016/j.amjmed.2013.06.025

37. Шабанова СШ, Ананьева ЛП, Попкова ТВ и др. Традиционные кардиоваскулярные факторы риска и атеросклероз у больных системной склеродермией. Научно- практическая ревматология. 2007;45(4):24-30 [Shabanova SS, Ananjeva LP, Popkova TV, et al. Traditional cardiovascular risk factors and atherosclerosis in patients with systemic sclerosis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2007;45(4):24- 30 (In Russ.)]. doi: 10.14412/1995-4484-2007-24-30

38. Tadic M, Cuspidi C, Pencic B, et al. Relationship between right ventricular remodeling and heart rate variability in arterial hypertension. J Hypertens. 2015 May;33(5):1090-7. doi: 10.1097/HJH.0000000000000511

39. Foocharoen C, Pussadhamma B, Mahakkanukrauh A, et al. Asymptomatic cardiac involvement in Thai systemic sclerosis: prevalence and clinical correlations with non-cardiac manifestations (preliminary report). Rheumatology (Oxford). 2015 Sep;54(9):1616-21. doi: 10.1093/rheumatology/kev096

40. Rosato E, Gigante A, Gasperini ML, et al. Nutritional status measured by body mass index is impaired and correlates with left ventricular mass in patients with systemic sclerosis. Nutrition. 2014 Feb;30(2):204-9. doi: 10.1016/j.nut.2013.07.025

41. Piccione MC, Bagnato G, Zito C, et al. Early identification of vascular damage in patients with systemic sclerosis. Angiology. 2011 May;62(4):338-43. doi: 10.1177/0003319710387918